{
    "clinical_study": {
        "@rank": "97582", 
        "arm_group": {
            "arm_group_label": "Treatment (porfimer sodium, image-guided I-PDT)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive porfimer sodium IV over 3-5 minutes on day 0. Approximately 44-52 hours after porfimer sodium administration, patients undergo image-guided I-PDT."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies the effects of interstitial photodynamic therapy in patients\n      with oropharynx or oral cavity cancer that has come back. Interstitial photodynamic therapy\n      uses a combination of laser light and a light-sensitive drug called porfimer sodium to\n      destroy tumors. During treatment a laser light is used to activate the drug. Interstitial\n      photodynamic therapy may be an effective treatment for oropharynx or oral cavity cancer."
        }, 
        "brief_title": "Interstitial Photodynamic Therapy in Treating Patients With Recurrent Oropharynx or Oral Cavity Cancer", 
        "condition": [
            "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", 
            "Recurrent Squamous Cell Carcinoma of the Oropharynx", 
            "Recurrent Verrucous Carcinoma of the Oral Cavity", 
            "Tongue Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Tongue Neoplasms", 
                "Carcinoma, Verrucous", 
                "Oropharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Demonstrate that our image-guided interstitial photodynamic therapy (I-PDT) dosimetry\n      system can be used to tailor this therapy to individual patients.\n\n      OUTLINE:\n\n      Patients receive porfimer sodium intravenously (IV) over 3-5 minutes on day 0. Approximately\n      44-52 hours after porfimer sodium administration, patients undergo image-guided I-PDT.\n\n      After completion of study treatment, patients are followed up at 1 month, 2 months, 4\n      months, and then every 2 months for up to 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2\n\n          -  Histologically confirmed recurrent squamous cell carcinoma of the oropharynx or oral\n             cavity\n\n          -  Tumor accessible for unrestricted illumination for interstitial photodynamic therapy\n             (PDT) (accessibility as determined by the physician)\n\n          -  Patients on chemotherapy for palliation\n\n          -  Life expectancy of at least 6 months in the judgment of the physician\n\n          -  Subjects of child-bearing potential must agree to use adequate contraceptive methods\n             (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry\n             and for the duration of study participation, should a woman become pregnant or\n             suspect she is pregnant while she or her partner is participating in this study, she\n             should inform her treating physician immediately\n\n          -  Subject or legal representative must understand the investigative nature of this\n             study and sign an Institutional Review Board approved written informed consent form\n             prior to receiving any study related procedure\n\n        Exclusion Criteria:\n\n          -  Radiotherapy within the last 2 months\n\n          -  Patients with known brain metastases should be excluded from this clinical trial\n\n          -  Tumor invading a major blood vessel (such as the carotid artery)\n\n          -  Tumor is not clearly shown on a computed tomography (CT) scan\n\n          -  Location and extension of the tumor precludes an effective I-PDT\n\n          -  Patients with porphyria, or with known hypersensitivity to porphyrins or\n             porphyrin-like compounds\n\n          -  While blood cell (WBC) < 4,000\n\n          -  Total serum bilirubin > 2.0 mg/dL\n\n          -  Serum creatinine > 2 mg/dl\n\n          -  Alkaline phosphatase (hepatic) > 3 times the upper limit of normal\n\n          -  Serum glutamic oxaloacetic transaminase (SGOT) > 3 times the upper limit of normal\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, acute exacerbation of congestive heart failure, unstable angina pectoris,\n             cardiac arrhythmia, or psychiatric illness/social situations that would limit\n             compliance with study requirements\n\n          -  Pregnant or nursing female subjects\n\n          -  Unwilling or unable to follow protocol requirements and the light exposure\n             precautions\n\n          -  Any condition which in the investigator's opinion deems the subject an unsuitable\n             candidate to receive study drug and therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068157", 
            "org_study_id": "I 235613", 
            "secondary_id": [
                "NCI-2014-00210", 
                "I 235613", 
                "P30CA016056"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (porfimer sodium, image-guided I-PDT)", 
                "description": "Given IV", 
                "intervention_name": "porfimer sodium", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CL-184116", 
                    "DHE", 
                    "dihematoporphyrin ether", 
                    "Photofrin II"
                ]
            }, 
            {
                "arm_group_label": "Treatment (porfimer sodium, image-guided I-PDT)", 
                "description": "Undergo image-guided I-PDT", 
                "intervention_name": "photodynamic therapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Light Infusion Therapy\u2122", 
                    "PDT", 
                    "therapy, photodynamic"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dihematoporphyrin Ether", 
                "Trioxsalen"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "contact": {
                "email": "ASKRPCI@roswellpark.org", 
                "last_name": "Roswell Park", 
                "phone": "877-275-7724"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14263"
                }, 
                "name": "Roswell Park Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Hassan Arshad", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II", 
        "overall_official": {
            "affiliation": "Roswell Park Cancer Institute", 
            "last_name": "Hassan Arshad", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A logistic model will be fit to the relationship between the probability of changes in tumor response with intra-tumoral light dose. Wald tests of the model effects will be performed to assess statistical significance at the 0.1 level of significance. A number of diagnostic plots and statistics will be calculated in the evaluation of the model fit.", 
            "measure": "Tumor response rate according to Response Evaluation Criteria in Solid Tumors 1.1", 
            "safety_issue": "No", 
            "time_frame": "Up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068157"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Roswell Park Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Roswell Park Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}